Should New Anti-Malarial Drugs be Subsidized?

Date

Sept. 25, 2006

Authors

Ramanan Laxminarayan, Ian Parry, David Smith, and Eili Klein

Publication

Working Paper

Reading time

1 minute

We use analytical and numerical models to explain and quantify the welfare effects of subsidies for artemisinin combination treatments (ACTs), a valuable new class of antimalarial drugs. There are two (second-best) efficiency rationales for such subsidies: by expanding drug use, they reduce infection transmission from one individual to another, and they slow the evolution of drug resistance by deterring use of substitute monotherapy drugs for which resistance emerges more rapidly than for ACTs. Our analysis merges epidemiological models of malaria transmission among individuals and mosquitoes, evolution of drug resistance, and economic models of the demand for alternative drugs; parameter values for the simulations are representative of malaria prevalence in sub-Saharan Africa. We find that large subsidies for ACT are welfare improving across many plausible scenarios for malaria transmission, drug-demand elasticities, and evolution of drug resistance; the benefits of the policy are often several times larger than the costs.

Download

Should New Anti-Malarial Drugs be Subsidized?

PDF — 0 bytes

Topics

Authors

Ramanan Laxminarayan

Ian Parry

David Smith

Eili Klein

Related Content

Media Highlight — Feb 3, 2025

E&E News: “Trump’s 10-for-1 Regs Order Jettisons Rulemaking Revamp”

RFF President and CEO Billy Pizer comments on the revision of Circular A-4, an important piece of federal guidance for cost-benefit analysis.

In Focus — Oct 22, 2024

In Focus: Partisan Views on Climate Change

This video shares insights from polling about how Americans' views on climate change differ depending on political affiliation, with Stanford University Professor and RFF University Fellow Jon Krosnick.

Issue Brief — Jul 10, 2024

The US Department of the Treasury’s Proposed Guidance for the Tech-Neutral Tax Credits

This issue brief outlines the questions answered by the US Department of the Treasury's guidance on technology-neutral tax credits, as well as those that have yet to be addressed.

Carbon Score — Jun 7, 2024

Carbon Scoring: An Initial Baseline

This analysis establishes an initial baseline for RFF’s carbon scoring work, comparing our current central projection, including the Inflation Reduction Act (IRA) and more recent policy developments, against a baseline scenario from 2022.